|1.||Okada, Kae: 3 articles (10/2013 - 01/2013)|
|2.||Ito, Yukako: 3 articles (10/2013 - 01/2013)|
|3.||Kobuchi, Shinji: 3 articles (10/2013 - 01/2013)|
|4.||Kuwano, Shota: 3 articles (10/2013 - 01/2013)|
|5.||Takada, Kanji: 3 articles (10/2013 - 01/2013)|
|6.||Imoto, Kazuki: 3 articles (10/2013 - 01/2013)|
|7.||Carlsson, Göran: 2 articles (10/2014 - 06/2012)|
|8.||Wettergren, Yvonne: 2 articles (10/2014 - 06/2012)|
|9.||Gustavsson, Bengt: 2 articles (10/2014 - 06/2012)|
|10.||Odin, Elisabeth: 2 articles (10/2014 - 06/2012)|
|1.||Colorectal Neoplasms (Colorectal Cancer)
07/01/2010 - "The value of dihydrouracil/uracil plasma ratios in predicting 5-fluorouracil-related toxicity in colorectal cancer patients."
10/01/2014 - "Pretherapeutic uracil and dihydrouracil levels in saliva of colorectal cancer patients are associated with toxicity during adjuvant 5-fluorouracil-based chemotherapy."
06/01/2012 - "Pretherapeutic uracil and dihydrouracil levels of colorectal cancer patients are associated with sex and toxic side effects during adjuvant 5-fluorouracil-based chemotherapy."
01/01/2007 - "The dihydrouracil/uracil ratios in plasma and toxicities of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer patients."
04/01/1999 - "Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage."
|2.||Dihydropyrimidine Dehydrogenase Deficiency
09/01/2009 - "The dihydrouracil/uracil ratio in plasma, clinical and genetic analysis for screening of dihydropyrimidine dehydrogenase deficiency in colorectal cancer patients treated with 5-fluorouracil."
01/01/2016 - "Here we describe an LCMS method for determination of uracil, thymine, thymidine, dihydrouracil, and dihydrothymine that are diagnostic biomarkers of MNGIE, pyrimidinuria, and dihydropyrimidinuria. "
08/01/2002 - "We established the first monoclonal antibody that reacted with uracil and thymine but not with pseudouridine, dihydrouracil, dihydrothymine, cytosine, uridine, or N-carbamyl-beta-alanine at the concentration of 100 microg/ml. The monoclonal antibody can be used to develop a simple screening assay for patients with dihydropyrimidine dehydrogenase deficiency. "
10/20/1995 - "As this system permits the simultaneous determination of urinary orotic acid, uracil, dihydrouracil, pseudouridine, xanthine, 2,8-dihydroxyadenine and succinyladenosine, it offers a useful method for the detection of orotic aciduria, dihydropyrimidine dehydrogenase deficiency, dihydropyrimidinuria, xanthinuria, adenine phosphoribosyltransferase deficiency and adenylosuccinase deficiency."
04/01/2002 - "Dihydrouracil (DU) and U levels in the urine and DPD activities in the resected tumors were measured. "
01/01/2013 - "Pre-therapeutic assessment of plasma dihydrouracil/uracil ratio for predicting the pharmacokinetic parameters of 5-fluorouracil and tumor growth in a rat model of colorectal cancer."
06/01/2013 - "We developed a pharmacokinetic/pharmacodynamic (PK/PD) model with the value of the plasma ratio of dihydrouracil (UH2)/uracil (Ura), which is a possible surrogate biomarker of hepatic dihydropyrimidine dehydrogenase activity, determined before 5-fluorouracil (5-FU) treatment to simulate the growth of tumors after 5-FU treatment in rats with colorectal cancer (CRC). "
|4.||Renal Insufficiency (Renal Failure)
01/01/2012 - "To determine and compare the ratio of uracil (U) to dihydrouracil (UH(2)) concentrations in plasma as an indicator of dihydropyrimidine dehydrogenase activity in clinically normal dogs and dogs with neoplasia or renal insufficiency. "
01/01/2012 - "Assessment of plasma uracil-to-dihydrouracil concentration ratio as an indicator of dihydropyrimidine dehydrogenase activity in clinically normal dogs and dogs with neoplasia or renal insufficiency."
|5.||Ornithine Carbamoyltransferase Deficiency Disease
|3.||Dihydrouracil Dehydrogenase (NADP) (Dihydropyrimidine Dehydrogenase)
|4.||Biological Markers (Surrogate Marker)
|2.||Drug Therapy (Chemotherapy)